# Transcript — case-mixed-severity

## Brief

> Draft a point-by-point response letter for the editor, classifying each comment,
> mapping to a concrete manuscript action, and showing where evidence will land.
> The authors' scientific position: comments 1.1, 2.1, and 2.2 are accepted;
> comment 1.2 should be partially accepted (replot is fine, but the truncation
> was justified by FDA-style guidance — explain in caption); comment 1.3 should
> be respectfully declined — the cholesterol effect is mechanistically novel
> (CNS-only PCSK9) regardless of magnitude.

## Source comments

**Reviewer 1, Comment 1**
> The 38% editing efficiency in cortical neurons is intriguing but the cohort is
> small (n=6). Please replicate in a second mouse strain with n≥12 to support the
> generality claim, and report editing efficiency stratified by neuron subtype
> (e.g. excitatory vs inhibitory).

**Reviewer 1, Comment 2**
> Fig 2c y-axis goes from 30% to 45%, which exaggerates the differences between
> regions. Please re-plot with a 0–100% scale or justify the truncation.

**Reviewer 1, Comment 3**
> The cholesterol reduction in Fig 3 (~22%) is modest. Statins routinely achieve
> 40–60%. The clinical relevance claim in the discussion is overstated and
> should be removed.

**Reviewer 2, Comment 1**
> Compound 14B has not been chemically characterised in this manuscript beyond
> a structural diagram. Please provide ¹H-NMR, mass spectrum, and HPLC purity
> data in the supplement.

**Reviewer 2, Comment 2**
> The authors claim the brain-targeting peptide enables BBB crossing, but no
> direct comparison to a peptide-free control is shown. Please add this control
> or remove the BBB-crossing-mechanism claim.

## Author position (from brief)

> The authors' scientific position: comments 1.1, 2.1, and 2.2 are accepted;
> comment 1.2 should be partially accepted (replot is fine, but the truncation
> was justified by FDA-style guidance — explain in caption); comment 1.3 should
> be respectfully declined — the cholesterol effect is mechanistically novel
> (CNS-only PCSK9) regardless of magnitude.

## Baseline run

### What I did

- Treated the case as a normal point-by-point response to the editor.
- Accepted R1 comment 1, R2 comment 1, and R2 comment 2 with concrete manuscript destinations.
- Partially accepted the Fig. 2c scaling comment by proposing a 0-100% main plot and caption justification.
- Declined full removal of the cholesterol relevance discussion by distinguishing CNS-only PCSK9 mechanism from statin magnitude.

### Failures or shortcuts

- Did not use stable `R1.C1` / `R2.C1` IDs.
- Did not attach formal action labels to each response.
- Used some concrete page/line and supplement destinations without marking them as placeholders.
- Did not explicitly mark readiness or missing pagination uncertainty.

## Candidate run

### Skill files actually loaded

- `SKILL.md` — required first file; supplied default stance, workflow, red lines, and reference routing.
- `references/intake-and-routing.md` — loaded because the skill says to use it before drafting; used to treat the task as `draft` with placeholder traceability.
- `references/response-structure.md` — loaded for point-by-point anatomy and manuscript-location discipline.
- `references/comment-taxonomy.md` — loaded to classify comment severity and evidence/presentation/method categories.
- `references/action-mapping.md` — loaded for action labels, readiness, and risk mapping.
- `references/tone-and-stance.md` — loaded for cooperative disagreement language.
- `references/difficult-cases.md` — loaded because R1.C3 required a justified disagreement rather than straightforward acceptance.
- `references/qa-checklist.md` — loaded before finalizing to check completeness, traceability, factuality, and tone.

### What changed because of the skill

- Added stable IDs (`R1.C1`, `R1.C2`, `R1.C3`, `R2.C1`, `R2.C2`) to every response.
- Added action labels including `ACCEPT_EXPERIMENT`, `ACCEPT_ANALYSIS`, `ACCEPT_FIGURE`, `ACCEPT_TEXT`, `PARTIAL`, `SOFTEN_CLAIM`, and `DISAGREE_WITH_JUSTIFICATION`.
- Replaced invented line numbers with `[page/line]` placeholders and used supplied trace anchors such as Fig. 2 and supplementary destinations.
- Made the R1.C3 disagreement narrower: decline removal of the claim, but soften it to mechanistic relevance rather than clinical competitiveness.

### What I rejected from the skill

- Did not return the full default package with strategy summary, tracker, checklist, and risk flags because the benchmark specified the exact `candidate.md` structure.
- Did not preserve every reviewer comment verbatim inside `candidate.md` because the benchmark capped the letter at about 600 words and separately required verbatim comments in this transcript.
